Aktis Oncology, Inc.

NASDAQ:AKTS

Biotechnology

Healthcare
$16.10 +0.47%

+$0.11 today

Market cap
$865.32M
Beta
1.10
P/E (TTM)
-28.7
EPS (TTM)
-$0.82
52W Low $14.72High $29.16

Volume 0.44M

Average 0.33M

AKTS Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Aktis Oncology, Inc.NASDAQ: AKTS

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin at -567.9%

Net margin was -567.9% in Q1 FY2026.

What to watch

Whether net margin reaches the consensus estimate from 5 analysts of -681.7% for the fiscal year ending Dec 2026, up from -980.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-567.9%+241.7 pp QoQ
Last fiscal yearDec 2025
-980.9%+1976.7 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1976.7 pp+299.3 pp-1677.4 pp
3 years—-635.7 pp—
5 years+821.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-980.9%
Year-over-year change
+1976.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How AKTS compares with its peers on the latest reported figures

  • AKTS's FY2025 net margin of -980.9% is the 4th highest of the 5 companies compared; the peer median is -194.9%.
  • Its year-over-year change of +1976.7 pp is the highest of 5, against a peer median of +91.0 pp.
AKTS Competitors Peer median
Net Margin for AKTS and competitors
Company Period LTM level YoY 3-year change
IMCRImmunocore Holdings plcLTM Mar 2026-4.9% +1.6 pp+21.3 pp
MGNXMacroGenics, Inc.LTM Mar 2026-44.8% -8.2 pp+29.9 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-345.0% +445.1 pp+477.7 pp
AKTSAktis Oncology, Inc.FY2025-980.9% +1976.7 pp—
IMNMImmunome, Inc.FY2025-3060.0% +180.4 pp—
AURAAura Biosciences, Inc.FY2025— ——
Peer median (excluding AKTS) -194.9%+91.0 pp+29.9 pp

Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue001.49M6.5M
Cost of Revenue0000
Gross Profit001.49M6.5M
Gross Margin——100.0%100.0%
Research & Development14.3M25.92M40.95M67.45M
Selling, General & Admin5.11M7.68M11.31M12.6M
Operating Expenses19.76M34.79M53.54M81.18M
Depreciation & Amortization445K1.2M1.58M2.33M
EBITDA(17.48M)(27.45M)(42.41M)(61.4M)
EBITDA Margin——-2851.7%-945.1%
Operating Income(19.76M)(34.79M)(52.05M)(74.68M)
Operating Margin——-3500.3%-1149.5%
Interest Income1.65M5.38M8.1M11.01M
Interest Expense0000
Other Income / Expenses1.84M6.15M8.07M10.95M
Income Before Tax(17.93M)(28.64M)(43.98M)(63.73M)
Pre-Tax Margin——-2957.6%-980.9%
Income Tax Expense0000
Net Income(17.93M)(28.64M)(43.98M)(63.73M)
Net Margin——-2957.6%-980.9%
EPS (Basic)(0.51)(0.82)(1.26)(1.19)
EPS (Diluted)(0.51)(0.82)(1.26)(1.19)
Weighted Avg Shares34.86M34.86M34.86M52.52M
Weighted Avg Shares (Diluted)34.86M34.86M34.86M52.52M

Aktis Oncology, Inc.

NASDAQ:AKTS

Intrinsic Alpha fair value

Locked

Current Price

$16.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.